On June 17, 2015, Capricor Therapeutics, Inc. (Nasdaq:CAPR) (http://capricor.com/), a Beverly Hills, California biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics for the treatment of diseases, announced the appointment of Houman Hemmati (image), M.D., Ph.D., to the newly created position of Vice President of Medical and Clinical Development for New Therapies. In this role, Dr. Hemmati will work to drive promising new therapies such as Capricor's exosome platform into clinical development as he works closely with the R&D, manufacturing, and product development teams. "Dr. Hemmati strengthens our team with valuable clinical development experience having driven multiple key high-profile products through the clinical trial process prior to joining Capricor. This timely addition to our management team comes as we expand our platform and work to bring new exosome therapeutics into clinical development next year," said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. "Our exosomes, which are nanometer-sized vesicles packed full of RNAs, have demonstrated exciting capabilities to date including the ability to enact various structural and functional changes therapeutically beneficial in animal models. Further our exosomes offer a broad spectrum of therapeutic potential primarily focused on their anti-inflammatory and anti-fibrotic properties that we are now poised to further develop." Prior to joining Capricor, Dr. Hemmati, an ophthalmologist, was Director of Clinical Development at Allergan, where his responsibilities included early- to late-stage clinical trial development of high-profile ophthalmic products such as Restasis-X as well as Allegan's androgen-based ophthalmic treatment and AGN 199201 for presbyopia. Prior to his time at Allergan, Dr.
Login Or Register To Read Full Story